MOms in REcovery (MORE) Study: Defining Optimal Care
Key facts
- Who runs it
- Trustees of Dartmouth College
- Where
- Augusta, Bangor, Bennington, Berlin Corners, Brattleboro, Keene, Lebanon, Manchester, and Nashua, United StatesSee the 10 sites
- Trial code
- Status
- Completed
- People taking part
- 2,510 people enrolled
- Started
- 30 Jul 2019
- Ended
- 31 Jan 2024
- Type of study
- Observational, 2 groups
- Treatments tested
- Observational Study
- Record updated
- 23 October 2026
Who can take part
- Age
- 16 years to 50 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Age 16 year and older,
- Identified opioid use disorder,
- Receiving prenatal care for current pregnancy at partner practice,
- Clinic-recorded diagnosis of opioid use disorder,
- Willing and able to provide informed consent
Who cannot take part
- Ward of the State
Where in United States
- Maine General HospitalAugusta, United States
- Eastern Maine Medical Center/Northern LightBangor, United States
- Southwestern Vermont Medical Center OB-GYNBennington, United States
- Central Vermont Medical CenterBerlin Corners, United States
- Brattleboro Memorial Hospital OB-GYNBrattleboro, United States
- Dartmouth Hitchcock Keene/Cheshire Medical Center OB-GYNKeene, United States
- Dartmouth Hitchcock Addiction Treatment, Moms in RecoveryLebanon, United States
- Dartmouth-Hitchcock Medical Center-OB/GYNLebanon, United States
- Dartmouth Hitchcock Bedford/ManchesterManchester, United States
- Dartmouth Hitchcock Nashua OB-GYNNashua, United States
About the trial
What the trial wants to find out
Northern New England has among the highest rates of opioid dependence in the U.S. This region also has among the highest rates of opioid-related deaths in the U.S., with a disproportionate high rate among pregnant women with opioid use disorder. Newborns impacted by OUD have increased risk of poor outcomes, including preterm birth and long hospitalization for neonatal withdrawal and other newborn complications. For pregnant women with OUD, medication treatment (MOUD) significantly reduces these risks. Many maternity care providers have begun to prescribe MOUD in their practices. Other practices have maintained the longstanding evidence-based standard of care, referral of patients with OUD to specialty treatment programs. Most pregnant women with OUD have other psychosocial needs, ranging from lack of housing and untreated mental health conditions, to need for parenting education and support. There is variability among practices in terms of types of other services provided to patients. Although pregnancy is a time when women are highly motivated to start MOUD, many women are also likely to discontinue MOUD postpartum due to loss of insurance coverage, difficulty transitioning to another provider, loss of motivation for treatment, or competing demands on time and resources as a new parent.
Read full original descriptionShow less
The challenge for patients, providers, and other stakeholders is to understand the relative advantage of the two MOUD models (receiving MOUD as part of maternity care or at a specialty program) for improving key outcomes for baby \& mother. A second challenge is to understand the relative contributions of onsite services such as mental health care, care coordination and parenting education to improved outcomes. Addressing these challenges is particularly important in rural areas where obstetric practices \& specialty care services are limited. Patients, providers \& other stakeholders need guidance in choosing the optimal models for building programs to provide maternity care for women with OUD.
The 2 groups in the trial
- Integrated Care
This is an observational study and no intervention will be administered. The Integrated Cohort consists of pregnant women with identified opioid use disorder who are receiving prenatal care in a maternity setting that provides medication assisted treatment for opioid use.
Treatment: Observational Study
- Referral-Based Care
This is an observational study and no intervention will be administered. The Referral-Based Cohort consists of pregnant women with identified opioid use disorder who are receiving prenatal care in a maternity setting and are referred to substance use treatment at a specialty care setting.
Treatment: Observational Study
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- MOms in REcovery (MORE): Defining Optimal Care for Pregnant Women and Infants
- Record updated
- 23 October 2026